Estimates of epilepsy prevalence, psychiatric co-morbidity and cost

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Estimates of epilepsy prevalence, psychiatric co-morbidity and cost. / Christensen, Jakob; Dreier, Julie Werenberg; Sun, Yuelian; Linehan, Christine; Tomson, Torbjörn; Marson, Anthony; Forsgren, Lars; Granbichler, Claudia A.; Trinka, Eugen; Illiescu, Catrinel; Malmgren, Kristina; Kjellberg, Jakob; Ibsen, Rikke; Jennum, Poul Jorgen; the ESBACE Consortium and ESBACE Collaborators.

I: Seizure, Bind 107, 2023, s. 162-171.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Christensen, J, Dreier, JW, Sun, Y, Linehan, C, Tomson, T, Marson, A, Forsgren, L, Granbichler, CA, Trinka, E, Illiescu, C, Malmgren, K, Kjellberg, J, Ibsen, R, Jennum, PJ & the ESBACE Consortium and ESBACE Collaborators 2023, 'Estimates of epilepsy prevalence, psychiatric co-morbidity and cost', Seizure, bind 107, s. 162-171. https://doi.org/10.1016/j.seizure.2022.06.010

APA

Christensen, J., Dreier, J. W., Sun, Y., Linehan, C., Tomson, T., Marson, A., Forsgren, L., Granbichler, C. A., Trinka, E., Illiescu, C., Malmgren, K., Kjellberg, J., Ibsen, R., Jennum, P. J., & the ESBACE Consortium and ESBACE Collaborators (2023). Estimates of epilepsy prevalence, psychiatric co-morbidity and cost. Seizure, 107, 162-171. https://doi.org/10.1016/j.seizure.2022.06.010

Vancouver

Christensen J, Dreier JW, Sun Y, Linehan C, Tomson T, Marson A o.a. Estimates of epilepsy prevalence, psychiatric co-morbidity and cost. Seizure. 2023;107:162-171. https://doi.org/10.1016/j.seizure.2022.06.010

Author

Christensen, Jakob ; Dreier, Julie Werenberg ; Sun, Yuelian ; Linehan, Christine ; Tomson, Torbjörn ; Marson, Anthony ; Forsgren, Lars ; Granbichler, Claudia A. ; Trinka, Eugen ; Illiescu, Catrinel ; Malmgren, Kristina ; Kjellberg, Jakob ; Ibsen, Rikke ; Jennum, Poul Jorgen ; the ESBACE Consortium and ESBACE Collaborators. / Estimates of epilepsy prevalence, psychiatric co-morbidity and cost. I: Seizure. 2023 ; Bind 107. s. 162-171.

Bibtex

@article{92ad238f21c7444895afae697177f2f9,
title = "Estimates of epilepsy prevalence, psychiatric co-morbidity and cost",
abstract = "Purpose: This study estimated epilepsy prevalence, psychiatric co-morbidity and annual costs associated with epilepsy. Methods: We used Danish national health registers to identify persons diagnosed with epilepsy and psychiatric disorders, and persons using antiseizure medication and persons using drugs for psychiatric disorders. We calculated the prevalence of epilepsy and co-morbid psychiatric disorders in Denmark on December 31, 2016, using information on epilepsy and psychiatric disorders based on combinations of hospital contacts and use of antiseizure and psychoactive medication. Further, direct and indirect annual costs associated with epilepsy were calculated using individual-level data from a range of socioeconomic registers. Results: There were 5,044,367 persons alive and living in Denmark on December 31, 2016, including 33,628 persons with at least one hospital contact with epilepsy in the previous five years (epilepsy prevalence 0.67% (0.69% males; 0.65% females)). Among these persons with epilepsy, we identified 12,562 (37.4%) persons with a psychiatric disorder or use of drugs used for psychiatric disorders as compared with 801,052 (15.9%) persons in the general population. The estimated total annual individual net costs associated with epilepsy was €30,683. Compared with prevalence estimates on December 31, 2006, the prevalence of epilepsy on December 31, 2016, was slightly higher in the older population and slightly lower in children Conclusions: Population estimates from national registers provide epilepsy prevalence estimates of approximately 0.6–0.7% - similar to previous reviews of epilepsy prevalence. In addition, the national sample allowed idenitfication of high prevalence of psychiatric disorders and high societal costs associated with epielspy.",
keywords = "Cost, Epidemiology, Prevalence, Psychiatric co-morbidity",
author = "Jakob Christensen and Dreier, {Julie Werenberg} and Yuelian Sun and Christine Linehan and Torbj{\"o}rn Tomson and Anthony Marson and Lars Forsgren and Granbichler, {Claudia A.} and Eugen Trinka and Catrinel Illiescu and Kristina Malmgren and Jakob Kjellberg and Rikke Ibsen and Jennum, {Poul Jorgen} and {the ESBACE Consortium and ESBACE Collaborators}",
note = "Publisher Copyright: {\textcopyright} 2022 The Author(s)",
year = "2023",
doi = "10.1016/j.seizure.2022.06.010",
language = "English",
volume = "107",
pages = "162--171",
journal = "Seizure : the journal of the British Epilepsy Association",
issn = "1059-1311",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Estimates of epilepsy prevalence, psychiatric co-morbidity and cost

AU - Christensen, Jakob

AU - Dreier, Julie Werenberg

AU - Sun, Yuelian

AU - Linehan, Christine

AU - Tomson, Torbjörn

AU - Marson, Anthony

AU - Forsgren, Lars

AU - Granbichler, Claudia A.

AU - Trinka, Eugen

AU - Illiescu, Catrinel

AU - Malmgren, Kristina

AU - Kjellberg, Jakob

AU - Ibsen, Rikke

AU - Jennum, Poul Jorgen

AU - the ESBACE Consortium and ESBACE Collaborators

N1 - Publisher Copyright: © 2022 The Author(s)

PY - 2023

Y1 - 2023

N2 - Purpose: This study estimated epilepsy prevalence, psychiatric co-morbidity and annual costs associated with epilepsy. Methods: We used Danish national health registers to identify persons diagnosed with epilepsy and psychiatric disorders, and persons using antiseizure medication and persons using drugs for psychiatric disorders. We calculated the prevalence of epilepsy and co-morbid psychiatric disorders in Denmark on December 31, 2016, using information on epilepsy and psychiatric disorders based on combinations of hospital contacts and use of antiseizure and psychoactive medication. Further, direct and indirect annual costs associated with epilepsy were calculated using individual-level data from a range of socioeconomic registers. Results: There were 5,044,367 persons alive and living in Denmark on December 31, 2016, including 33,628 persons with at least one hospital contact with epilepsy in the previous five years (epilepsy prevalence 0.67% (0.69% males; 0.65% females)). Among these persons with epilepsy, we identified 12,562 (37.4%) persons with a psychiatric disorder or use of drugs used for psychiatric disorders as compared with 801,052 (15.9%) persons in the general population. The estimated total annual individual net costs associated with epilepsy was €30,683. Compared with prevalence estimates on December 31, 2006, the prevalence of epilepsy on December 31, 2016, was slightly higher in the older population and slightly lower in children Conclusions: Population estimates from national registers provide epilepsy prevalence estimates of approximately 0.6–0.7% - similar to previous reviews of epilepsy prevalence. In addition, the national sample allowed idenitfication of high prevalence of psychiatric disorders and high societal costs associated with epielspy.

AB - Purpose: This study estimated epilepsy prevalence, psychiatric co-morbidity and annual costs associated with epilepsy. Methods: We used Danish national health registers to identify persons diagnosed with epilepsy and psychiatric disorders, and persons using antiseizure medication and persons using drugs for psychiatric disorders. We calculated the prevalence of epilepsy and co-morbid psychiatric disorders in Denmark on December 31, 2016, using information on epilepsy and psychiatric disorders based on combinations of hospital contacts and use of antiseizure and psychoactive medication. Further, direct and indirect annual costs associated with epilepsy were calculated using individual-level data from a range of socioeconomic registers. Results: There were 5,044,367 persons alive and living in Denmark on December 31, 2016, including 33,628 persons with at least one hospital contact with epilepsy in the previous five years (epilepsy prevalence 0.67% (0.69% males; 0.65% females)). Among these persons with epilepsy, we identified 12,562 (37.4%) persons with a psychiatric disorder or use of drugs used for psychiatric disorders as compared with 801,052 (15.9%) persons in the general population. The estimated total annual individual net costs associated with epilepsy was €30,683. Compared with prevalence estimates on December 31, 2006, the prevalence of epilepsy on December 31, 2016, was slightly higher in the older population and slightly lower in children Conclusions: Population estimates from national registers provide epilepsy prevalence estimates of approximately 0.6–0.7% - similar to previous reviews of epilepsy prevalence. In addition, the national sample allowed idenitfication of high prevalence of psychiatric disorders and high societal costs associated with epielspy.

KW - Cost

KW - Epidemiology

KW - Prevalence

KW - Psychiatric co-morbidity

U2 - 10.1016/j.seizure.2022.06.010

DO - 10.1016/j.seizure.2022.06.010

M3 - Journal article

C2 - 35811222

AN - SCOPUS:85133777678

VL - 107

SP - 162

EP - 171

JO - Seizure : the journal of the British Epilepsy Association

JF - Seizure : the journal of the British Epilepsy Association

SN - 1059-1311

ER -

ID: 331315087